OncoMatch/Ovarian Cancer/BRCA2
Ovarian CancerBRCA2 Clinical Trials
Germline and somatic BRCA2 pathogenic variants occur in approximately 10–15% of high-grade serous ovarian carcinoma. BRCA2-mutant tumors are highly sensitive to platinum chemotherapy and PARP inhibitors; BRCA2 somatic reversion mutations are a key mechanism of acquired PARP inhibitor resistance. Active trials study PARP inhibitor maintenance, combination strategies targeting HRD pathway co-vulnerabilities, and approaches to overcome or prevent PARP inhibitor resistance.
Top recruiting BRCA2 Ovarian Cancer trials
Ranked by phase and US site count. See all 18 trials matched to your profile →
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers
Aurigene Discovery Technologies Limited
Browse other molecular targets with active Ovarian Cancer trials.